Abstract
Background
Drug use has rarely been studied in multiple system atrophy (MSA) while such patients receive many treatments based on weak evidence.
Objective
To analyze drug use from the database of the French MSA Reference Center, and to compare it with data from patients with Parkinson disease (PD).
Methods
Medication of 147 MSA and 180 age- and sex-matched PD patients was analyzed. Motor and autonomic symptoms were explored in MSA patients by the SCOPA-Autonomic and Unified MSA Rating Scale (UMSARS).
Results
MSA and PD patients received a mean of five different drugs. MSA patients were more frequently exposed to laxatives, antidiabetic medications, antihypotensives, muscarinic antagonists, alpha-adrenergic blockers, and antidepressants. Levodopa consumption was less in MSA-C (cerebellar) patients compared with MSA-P (parkinsonian) and PD patients. Dopamine agonists were more consumed by PD than MSA patients. MSA patients with more severe disability received more laxatives, anticoagulants, and antidepressants. MSA-P patients received more analgesics. “Probable” MSA patients received more antihypotensives and less alpha-adrenergic blockers. Patients with higher SCOPA-Autonomic scores were more frequently on antihypotensives or antidepressants. Drug associations leading to potential adverse interactions were uncommon (usually <5 %).
Conclusions
Some differences in drug use between MSA and PD patients were observed and expected, including those used for the relief of parkinsonian motor symptoms, autonomic dysfunction, and depression. Many of these drugs are frequently used in MSA in the absence of well-established, positive, benefit-risk evaluations, thus calling for better assessments. The reason why other medications, including anti-diabetic medications, were more consumed by MSA patients remains unclear and deserves further exploration.
Similar content being viewed by others
References
Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy: an update. Lancet Neurol. 2009;8:1172–8.
Wenning GK, Geser F, Poewe W. Therapeutic strategies in multiple system atrophy. Mov Disord. 2005;20(Suppl 12):S67–76.
Lee D, Bergman U. Studies of drug utilization. In: Strom BL, editor. Pharmacoepidemiology. Chichester: Wiley; 2000. p. 463–82.
Centre de référence de l’atrophie multysistématisée. http://www.chu-toulouse.fr/-centre-de-reference-de-l-atrophie-multisystématisée (Accessed 2013 Oct. 15).
Les Maladies Rares. http://www.sante.gouv.fr/les-maladies-rares.html (Accessed 2013 Oct. 15).
Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord. 2004;19:1391–402.
Damon-Perriere N, Foubert-Samier A, De Cock VC, et al. Assessment of the SCOPA-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time. Parkinsonism Relat Disord. 2012;18:612–5.
Pavy-Le TA, Amarenco G, Duerr S, et al. The movement disorders task force review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011;26:1985–92.
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–6.
Perez-Lloret S, Rey MV, Fabre N, et al. Do Parkinson’s disease patients disclose their adverse events spontaneously? Eur J Clin Pharmacol. 2012;68:857–65.
Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology. 1992;42:1142–6.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2012, Oslo 2011.
Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25:2649–53.
Fahn S, Elton RL, Members of the UPDRS committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Mardsen CD, Goldstein M, editors. Recent developments in Parkinson’s disease. New York: McMillan; 1987. p. 153–63.
Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998;25:1032–7.
Kollensperger M, Geser F, Ndayisaba JP, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European Multiple System Atrophy Registry. Mov Disord. 2010;25:2604–12.
Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy: American Autonomic Society and American Academy of Neurology. Clin Auton Res. 1998;8:359–62.
Perez-Lloret S, Rascol O. Dopamine receptor agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010;24:941–68.
Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F, et al. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 2009;24:1111–24.
Colosimo C, Morgante L, Antonini A, et al. Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol. 2010;257:5–14.
Papatsoris AG, Papapetropoulos S, Singer C, et al. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn. 2008;27:22–7.
Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst. 2000;79:191–5.
Cameron AP, Jimbo M, Heidelbaugh JJ. Diagnosis and office-based treatment of urinary incontinence in adults: part two. Treatment. Ther Adv Urol. 2013;5:189–200.
Wenning GK, Colosimo C, Geser F, et al. Multiple system atrophy. Lancet Neurol. 2004;3:93–103.
Tison F, Yekhlef F, Chrysostome V. Depression and self-reported depressive symptoms in multiple system atrophy compared to Parkinson’s disease. Mov Disord. 2006;21:1056–7.
Bondon-Guitton E, Perez-Lloret S, Bagheri H, et al. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–31.
Licht CM, de Geus EJ, van Dyck R, et al. Longitudinal evidence for unfavorable effects of antidepressants on heart rate variability. Biol Psychiatry. 2010;68:861–8.
Cereda E, Barichella M, Pedrolli C, et al. Diabetes and risk of Parkinson’s disease: a systematic review and meta-analysis. Diabetes Care. 2011;34:2614–23.
Chrysostome V, Tison F, Yekhlef F, et al. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology. 2004;23:201–8.
Farzamnia H, Rabiei K, Sadeghi M, et al. The predictive factors of recurrent deep vein thrombosis. ARYA Atheroscler. 2011;7:123–8.
Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25:1077–81.
Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11:83–94.
Schmidt C, Berg D, Prieur S, et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord. 2009;24:2136–42.
Conflict of interest
MVR, SPLL, APL, WM, and FT do not have any conflicts of interest to disclose in relation to this study. OR has acted as an advisor for many pharmaceutical companies developing treatments for MSA. No funding was received for the conduct of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rey, M.V., Perez-Lloret, S., Pavy-Le Traon, A. et al. A Cross-Sectional Study on Drug Use in Multiple System Atrophy. CNS Drugs 28, 483–490 (2014). https://doi.org/10.1007/s40263-014-0159-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-014-0159-1